Chronic Lymphocytic Leukemia
January 2024 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Chronic Lymphocytic Leukemia abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Chronic Lymphocytic Leukemia. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Chronic Lymphocytic Leukemia. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Chronic Lymphocytic Leukemia every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Prognosis of older adults with chronic lymphocytic leukemia: A Surveillance, Epidemiology, and End Results-Medicare cohort study.
Authors:Duchesneau ED, McNeill AM, Schary W, Pate V, Lund JL
Institution:Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, 135 Dauer Drive, 2101 McGavran-Greenberg Hall CB #7435, Chapel Hill, NC 27599-7435, United States of America. Electronic address: emiliedd@live.unc.edu.
Journal:J Geriatr Oncol. 2023 Nov;14(8):101602. doi: 10.1016/j.jgo.2023.101602. Epub 2023 Sep 9.

2:Pure red cell aplasia occurring during ibrutinib therapy for chronic lymphocytic leukemia.
Authors:Wang L, Wu S, Yu G, Sui X, Chu X, Liu X
Institution:Department of Hematology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China.
Journal:J Oncol Pharm Pract. 2023 Dec;29(8):2031-2036. doi: 10.1177/10781552231189192. Epub 2023 Jul 30.

3:Trends of chronic lymphocytic leukemia incidence and mortality in the United States: a population-based study over the last four decades.
Authors:Alabrach Y, Mahmoud AA, Abdelhay A, Mansour M, Adra S
Institution:Medical Internship, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates.; Medical Internship, Al Qassimi Hospital, Sharjah, United Arab Emirates.
Journal:Expert Rev Hematol. 2023 Jul-Dec;16(10):785-791. doi: 10.1080/17474086.2023.2243385. Epub 2023 Aug 1.

4:Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients.
Authors:Mattsson A, Sylvan SE, Axelsson P, Ellin F, Kjellander C, Larsson K, Lauri B, Lewerin C, Scharenberg C, Tätting L, Johansson H, Österborg A, Hansson L
Institution:Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Journal:Eur J Haematol. 2023 Nov;111(5):715-721. doi: 10.1111/ejh.14065. Epub 2023 Jul 27.

5:Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review.
Authors:Islam P
Institution:Memorial Sloan Kettering Cancer Center, 530 E 74th St, New York, NY, 10021, USA. islamp@mskcc.org.
Journal:Curr Treat Options Oncol. 2023 Sep;24(9):1259-1273. doi: 10.1007/s11864-023-01112-0. Epub 2023 Jul 6.

6:Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency.
Authors:Rigolin GM, Olimpieri PP, Summa V, Celant S, Scarfò L, Tognolo L, Ballardini MP, Urso A, Sessa M, Gambara S, Cura F, Fortini M, Ghia P, Cuneo A, Russo P
Institution:Hematology unit, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.; Italian Medicines Agency, Rome, Italy.
Journal:Blood Cancer J. 2023 Jun 28;13(1):99. doi: 10.1038/s41408-023-00865-z.

7:Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia.
Authors:Guru Murthy GS, Atallah E
Institution:Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Journal:Hematol Oncol Stem Cell Ther. 2023 May 23;16(4):346-350. doi: 10.56875/2589-0646.1039.

8:Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation.
Authors:Roccograndi LM, Lovell AR, Ferrajoli A, Thompson PA, Burger JA, Wierda WG, Jain N, Rausch CR
Institution:Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Journal:Leuk Lymphoma. 2023 Sep;64(9):1554-1561. doi: 10.1080/10428194.2023.2223740. Epub 2023 Jun 15.

9:Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study.
Authors:Moreno C, Solman IG, Tam CS, Grigg A, Scarfò L, Kipps TJ, Srinivasan S, Mali RS, Zhou C, Dean JP, Szafer-Glusman E, Choi M
Institution:Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.; University of California San Diego, La Jolla, CA.
Journal:Blood Adv. 2023 Sep 26;7(18):5294-5303. doi: 10.1182/bloodadvances.2023010236.

10:Richter Transformation of Chronic Lymphocytic Leukemia-Are We Making Progress?
Authors:Audil HY, Kosydar SR, Larson DP, Parikh SA
Institution:Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. Parikh.Sameer@mayo.edu.
Journal:Curr Hematol Malig Rep. 2023 Oct;18(5):144-157. doi: 10.1007/s11899-023-00701-y. Epub 2023 Jun 9.

11:Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
Authors:Odetola O, Ma S
Institution:Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, 676 North Saint Clair Street, Suite 805, Chicago, IL, 60611, USA. Oluwatobi.odetola@northwestern.edu.
Journal:Curr Hematol Malig Rep. 2023 Oct;18(5):130-143. doi: 10.1007/s11899-023-00700-z. Epub 2023 Jun 6.

12:Pregnancy Course of 10 Women Diagnosed with Chronic Lymphocytic Leukemia.
Authors:Tadmor T, Melamed G, Alapi H, Gazit S, Patalon T, Rokach L
Institution:Hematology Unit, Bnai Zion Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.; Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Journal:Acta Haematol. 2023;146(5):379-383. doi: 10.1159/000531400. Epub 2023 Jun 5.

13:Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study.
Authors:Bravo J, Baltasar Tello P, González Garcia E, Ríos Herranz E, Páyer AR, Terol Castera MJ, Champ D, Medina Perez A, Gironella M, Fernández Zarzoso M, Forés R, Delgado J, Garcia-Marco JA
Institution:Molecular Cytogenetics Unit, Hematology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
Journal:Leuk Lymphoma. 2023 May;64(5):913-926. doi: 10.1080/10428194.2023.2216327. Epub 2023 May 31.

14:An update on the efficacy of Venetoclax for chronic lymphocytic leukemia.
Authors:Lovell AR, Sawyers J, Bose P
Institution:MD Anderson Cancer Center, Division of Pharmacy, Houston, TX, USA.; MD Anderson Cancer Center, Department of Leukemia, Division of Cancer Medicine, Houston, TX, USA.
Journal:Expert Opin Pharmacother. 2023 May-Aug;24(11):1307-1316. doi: 10.1080/14656566.2023.2218545. Epub 2023 May 29.

15:Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Plus Anti-CD20 Antibody Therapy Compared With Chemoimmunotherapy as Front-line Treatment for Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Authors:Nguyen TT, Thanh Nhu N, Tran VK, Van Cau N, Lin CF
Institution:International Ph.D. Program in Medicine.; Graduate Institute of Medical Sciences.
Journal:J Immunother. 2023 Oct 1;46(8):299-309. doi: 10.1097/CJI.0000000000000471. Epub 2023 May 23.

16:Impact of type 2 diabetes on mortality, cause of death, and treatment in chronic lymphocytic leukemia.
Authors:Rotbain EC, Allmer C, Rostgaard K, Andersen MA, Vainer N, da Cunha-Bang C, Parikh SA, Rabe KG, Hjalgrim H, Frederiksen H, Slager SL, Niemann CU
Institution:Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
Journal:Am J Hematol. 2023 Aug;98(8):1236-1245. doi: 10.1002/ajh.26964. Epub 2023 May 22.

17:Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias.
Authors:Nikitin E, Kislova M, Morozov D, Belyakova V, Suvorova A, Sveshnikova J, Vyscub G, Matveeva I, Shirokova M, Shipaeva A, Klitochenko T, Makarovskaya P, Dmitrieva E, Biderman B, Sudarikov A, Obukhova T, Samoilova O, Kaplanov K, Konstantinova T, Mayorova O, Poddubnaya I, Ptushkin V
Institution:State Budgetary Healthcare Institution of the city of Moscow City Clinical Hospital named after S.P. Botkin of Moscow City Healthcare Department, Moscow, Russian Federation. eugene_nikitin@mail.ru.
Journal:Leukemia. 2023 Jul;37(7):1464-1473. doi: 10.1038/s41375-023-01891-3. Epub 2023 May 18.

18:First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Authors:Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber PB, Tadmor T, Lindström V, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Nösslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, van der Klift M, Jäger U, Leys MBL, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink JC, Widmer A, Simon F, De Silva N, Fink AM, Bahlo J, Fischer K, Wendtner CM, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Levin MD, van Oers M, Geisler C, Stilgenbauer S, Hallek M
Institution:From the Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Dusseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne (B.E., M.F., C.Z., S.R., F.S., A.-M.F., J.B., K.F., K.A.K., M. Hallek), the Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen (J.T.), the Division of Chronic Lymphocytic Leukemia, Department of Internal Medicine III, University of Ulm, Ulm (C.S., E.T., S.S.), Group Practice for Hematology and Oncology, Dresden (T.I.); the Hematology-Oncology Center, Wurzburg (B.S.), Specialist Medical Practice of Hematology and Oncology, Mutlangen (H.H.), the Department of Hematology, Clinic for Hematology and Oncology, Centrum of Oncology, Bruderhospital St. Josef, Paderborn (T.G.), the Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig Maximilian University, Munich (C.-M.W.); and the Department of Hematology, Univ
Journal:N Engl J Med. 2023 May 11;388(19):1739-1754. doi: 10.1056/NEJMoa2213093.

19:Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia.
Authors:Roeker LE, DerSarkissian M, Ryan K, Chen Y, Duh MS, Wahlstrom SK, Hakre S, Yu L, Guo H, Mato AR
Institution:CLL Program, Leukemia Service, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
Journal:Blood Adv. 2023 Aug 22;7(16):4291-4301. doi: 10.1182/bloodadvances.2023009739.

20:Ofatumumab regimens in chronic lymphocytic leukemia: a meta-analysis.
Authors:Ashoub MH, Naseri A, Mohammadi P, Mohammadi M
Institution:Department of Hematology and Medical Laboratory Sciences, Faculty of Allied Medicine, Kerman University of Medical Sciences, Kerman, Iran.; Cellular and Molecular Research Center, Gerash University of Medical Sciences, Gerash, Iran. masoud.mohammadi1989@yahoo.com.
Journal:Ann Hematol. 2023 Jun;102(6):1301-1306. doi: 10.1007/s00277-023-05246-x. Epub 2023 May 3.

21:Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.
Authors:Shadman M, Manzoor BS, Sail K, Tuncer HH, Allan JN, Ujjani C, Emechebe N, Kamalakar R, Coombs CC, Leslie L, Barr PM, Brown JR, Eyre TA, Rampotas A, Schuh A, Lamanna N, Skarbnik A, Roeker LE, Bannerji R, Eichhorst B, Fleury I, Davids MS, Alhasani H, Jiang D, Hill BT, Schuster SJ, Brander DM, Pivneva I, Burne R, Guerin A, Mato AR
Institution:Fred Hutch Cancer Center and University of Washington, Seattle, WA.; CLL Program, Leukemia Service, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
Journal:Clin Lymphoma Myeloma Leuk. 2023 Jul;23(7):515-526. doi: 10.1016/j.clml.2023.03.010. Epub 2023 Mar 24.

22:Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity.
Authors:Gordon MJ, Jones JE, George B, Peterson C, Burger JA, Jain N, Keating M, Wierda WG, Durand JB, Ferrajoli A
Institution:Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Division of Cancer Medicine, Houston, Texas, USA.
Journal:Cancer. 2023 Jul 15;129(14):2192-2200. doi: 10.1002/cncr.34787. Epub 2023 Apr 5.

23:Current therapies for chronic lymphocytic leukemia: risk and prophylaxis strategies for secondary/opportunistic infections.
Authors:Diella L, Bavaro DF, Loseto G, Pasciolla C, Minoia C, Di Gennaro D, Belati A, De Candia MS, Di Gennaro F, Saracino A, Guarini A
Institution:Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari 'Aldo Moro', Bari, Italy.; IRCCS Istituto Tumori 'Giovanni Paolo II', Hematology Unit, Bari, Italy.
Journal:Expert Rev Hematol. 2023 Apr;16(4):267-276. doi: 10.1080/17474086.2023.2192918. Epub 2023 Apr 10.

24:Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR).
Authors:Špaček M, Smolej L, Šimkovič M, Nekvindová L, Křístková Z, Brychtová Y, Panovská A, Mašlejová S, Bezděková L, Écsiová D, Vodárek P, Zuchnická J, Mihályová J, Urbanová R, Turcsányi P, Lysák D, Novák J, Brejcha M, Líkařová T, Vodička P, Baranová J, Trněný M, Doubek M
Institution:1st Department of Medicine - Haematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Nove M?sto, Czech Republic.; Department of Internal Medicine - Haematology and Oncology, University Hospital, Brno, Czech Republic.
Journal:Br J Haematol. 2023 Jul;202(1):40-47. doi: 10.1111/bjh.18736. Epub 2023 Mar 27.

25:Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.
Authors:Shadman M
Institution:Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Journal:JAMA. 2023 Mar 21;329(11):918-932. doi: 10.1001/jama.2023.1946.

26:SOHO State of the Art Updates and Next Questions | Infections in Chronic Lymphocytic Leukemia Patients: Risks and Management.
Authors:Gargiulo E, Ribeiro EFO, Niemann CU
Institution:Tumor-Stroma Interactions, Department of Oncology, Luxembourg Institute of Health, Luxembourg City, Luxembourg; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; PERSIMUNE, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark.; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Center of Oncology and Hematology, Hospital Santa Lucia Sul, Brasilia, Brazil; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. Electronic address: carsten.utoft.niemann@regionh.dk.
Journal:Clin Lymphoma Myeloma Leuk. 2023 May;23(5):322-332. doi: 10.1016/j.clml.2023.02.001. Epub 2023 Feb 10.

27:Risks and outcomes of hospitalizations in patients with chronic lymphocytic leukemia admitted with immune thrombocytopenia: an analysis of the National Inpatient Sample Database.
Authors:Ammad Ud Din M, Mahmud A, Mostafa M, Shahzad M, Liaqat H, Pinilla-Ibarz J, Jaglal M
Institution:Hematology/Oncology, University of South Florida, Tampa, FL, USA. Mohammad.Ammad-ud-din@moffitt.org.; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Journal:Ann Hematol. 2023 Apr;102(4):889-895. doi: 10.1007/s00277-023-05133-5. Epub 2023 Feb 13.

28:Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia.
Authors:Wallace DS, Zent CS, Baran AM, Reagan PM, Casulo C, Rice G, Friedberg JW, Barr PM
Institution:Wilmot Cancer Institute and Department of Medicine, University of Rochester, Rochester, NY.
Journal:Blood Adv. 2023 Jun 13;7(11):2496-2503. doi: 10.1182/bloodadvances.2022009382.

29:Adherence and quality of life in patients with chronic lymphocytic leukemia treated with oral antineoplastic drugs.
Authors:Ochagavía Sufrategui M, Gil Lemus MÁ, Yáñez San Segundo L, Amado Diago CA, Barbadillo Villanueva S, Martínez Callejo V, Villacañas Palomares MV, Valero Domínguez M
Institution:Servicio de Farmacia Hospitalaria, Hospital Universitario Marques de Valdecilla, Santander, Espana. Electronic address: maria.ochagavia@scsalud.es.
Journal:Farm Hosp. 2023 Mar-Apr;47(2):69-74. doi: 10.1016/j.farma.2022.11.006. Epub 2023 Jan 2.

30:Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Authors:Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N, O'Brien SM, Tam CS, Qiu L, Zhou K, Simkovic M, Mayer J, Gillespie-Twardy A, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Salmi T, Wang MD, Fu L, Li J, Wu K, Cohen A, Shadman M
Institution:From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Koln Dusseldorf, Cologne, Germany (B.E.); St. James's University Hospital, Leeds, United Kingdom (P.H.); Maria Sk?odowska-Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice (S.G.), the Department of Hematology and Transplantology, Medical University of Gda?sk, Gda?sk (A.M.), and the Medical University of Lodz, Lodz (T.R.) - all in Poland; Herbert Irving Comprehensive Cancer Center, Columbia University, New York (N.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine (S.M.O.), and BeiGene USA, San Mateo (T.S., M.-D.-Y.W., L.F., J.L.
Journal:N Engl J Med. 2023 Jan 26;388(4):319-332. doi: 10.1056/NEJMoa2211582. Epub 2022 Dec 13.

31:Richter transformation in Chronic Lymphocytic Leukemia.
Authors:Innocenti I, Benintende G, Tomasso A, Fresa A, Autore F, Larocca LM, Laurenti L
Institution:Sezione di Ematologia, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario a. Gemelli IRCCS, Rome, Italy.
Journal:Hematol Oncol. 2023 Aug;41(3):293-300. doi: 10.1002/hon.3106. Epub 2022 Nov 30.

32:Ibrutinib and Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Focus on Atrial Fibrillation and Ventricular Tachyarrhythmias/Sudden Cardiac Death.
Authors:Boriani G, Menna P, Morgagni R, Minotti G, Vitolo M
Institution:Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.
Journal:Chemotherapy. 2023;68(2):61-72. doi: 10.1159/000528019. Epub 2022 Nov 10.

33:Novel combination approaches with targeted agents in frontline chronic lymphocytic leukemia.
Authors:Lipsky AH, Lamanna N
Institution:Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York, USA.
Journal:Cancer. 2023 Jan 1;129(1):18-31. doi: 10.1002/cncr.34510. Epub 2022 Nov 3.

34:Vaccination efficacy in patients with chronic lymphocytic leukemia.
Authors:Wang KY, Shah P, Skavla B, Fayaaz F, Chi J, Rhodes JM
Institution:Department of Internal Medicine, Northwell Health, Manhasset, NY, USA.; Department of Hematology Oncology, Northwell Health, Manhasset, NY, USA.
Journal:Leuk Lymphoma. 2023 Jan;64(1):42-56. doi: 10.1080/10428194.2022.2133538. Epub 2022 Oct 21.

35:Outcomes of Patients Diagnosed With Chronic Lymphocytic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results From a Tertiary Care Center.
Authors:Linn SM, Nampoothiri RV, Chen C, Pasic I, Al-Shaibani Z, Lam W, Law AD, Michelis FV, Kim DDH, Gerbitz A, Lipton J, Kumar R, Mattsson J, Viswabandya A
Institution:Hans Messner Allogeneic Blood and Marrow Transplantation Program, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
Journal:Hematol Oncol Stem Cell Ther. 2023 Apr 4;16(3):230-237. doi: 10.1016/j.hemonc.2021.09.008.

For a FREE PREVIEW of the Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Chronic Lymphocytic Leukemia...
at a Special 25% Discount


Medifocus Guidebook on Chronic Lymphocytic Leukemia

Updated: January 11, 2024
168 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Chronic Lymphocytic Leukemia is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $39.95
  • Less 25% Discount = - $10.00
  • Discounted Price = $29.95(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $26.60
  • Less 25% Discount = - $6.65
  • Discounted Price = $19.95

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 25% discount when you order your Guidebook by phone.

To receive your 25% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

CL642050520

Coupon Expires: August 22, 2024



What Our Customers Are Saying...

"I was recently diagnosed with CLL and searched all over the Web for information. I found the MediFocus Guidebook on Chronic Lymphocytic Leukemia to be a very useful resource. The information about chemotherapy was most important to me as well as recent studies concerning general treatments for this condition. The most valuable information was contained in the extensive references listed which were easy to access with a simple 'mouse' click. You are welcome to use my name as a reference."
G.C.
Coedpoeth, United Kingdom



  
Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2024 Medifocus, Inc. All rights reserved.